Get to know our clinical trials
Clinical trial of efficacy and safety for the immune-mediated prevention of CMV infection in low-risk kidney transplantation. (INMUNOVIR Study)
THE MAIN OBJECTIVE OF THE STUDY IS TO DETERMINE THE EFFECTIVENESS OF A NEW PREVENTION STRATEGY FOR AVOIDING CYTOMEGALOVIRUS (CMV) INFECTION IN PATIENTS WHO HAVE RECEIVED A KIDNEY TRANSPLANT.
Status
In recruitment
headquarters
Pamplona
Technical Summary
- CLINICAL TRIAL OF EFFICACY AND SAFETY FOR THE IMMUNE-MEDIATED PREVENTION OF CMV INFECTION IN LOW-RISK KIDNEY TRANSPLANTATION. (INMUNOVIR STUDY).
- Code EudraCT: 2025-520742-29-00
- Protocol number: FCO-INM-2024-01
- Promoter: Fundación para la Investigación Biomédica de Córdoba (FIBICO)
- Molecule/Drug: Valganciclovir
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.